Shin Nippon Biomedical Laboratories, Ltd. (2395.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Shin Nippon Biomedical Laboratories, Ltd.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
1522
First IPO Date
March 08, 2004
Key Executives
| Name | Title | Pay | Year Born |
| Ryoichi Nagata | President, Chairman, Chief Executive Officer, Group Chief Financial Officer, Fisheries Business Officer & Chief Health Officer | 144.06M | 1958 |
| Satoshi Matsumoto | Managing Executive Officer & GM of Fisheries Division | 0 | 1968 |
| Hideshi Tsusaki | Executive MD, Director, Head of Tech. Inf., Overseas Sales, NHP ARC & Global Business Dev. | 0 | 1967 |
| Ichiro Nagata | Sr. Executive VP, COO, Head of CRO Business, Head of Hospitality Business & Director | 0 | 1985 |
| Shu-Ichi Kanazashi | Managing Executive Officer, CMO and General Manager of TR Business Division | 0 | 1960 |
| Kyomi Nagatoshi | Senior Managing Executive Officer, Head of General Affairs & Human Resources and Director | 0 | 1966 |
| Shinji Nitanda | Senior MD of Corporate Development & Corporate Tax Administration and Director | 0 | 1968 |
| Fumihiko Makino | Senior Executive Officer, Financial Controller and GM of Finance & Accounting | 0 | N/A |
| Ken Takanashi | Executive Vice President of Group Corporate Management & Global Business & Director | 0 | 1964 |
| Terumasa Hirai | Managing Executive Officer & President and Representative Director of SNBL Ina Research Center | 0 | N/A |
| Toshiyuki Iwata | Managing Executive Officer, R/PR Division Manager & Sustainability Officer | 0 | N/A |
Description
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
